Board summary
Key figures
33,476
Registered population
60.6% aged 18–64
16.5%
Aged 65+
ICB 19.9% · England 17.9%
18.7%
Ethnic minority (non-White)
6.6% Asian · England 9.6%
28.2%
In IMD quintile 1
ICB 17.1% · England 21.0%
~7,410
Core20 residents (est.)
Resident basis; registered basis ~9,387 · see page 3
5,273
Hypertension register
+1.77% in 3 yrs · England +5.60%
299
SMI register
10.5% of Medway (LAD)'s
756
COPD register
Reviews -4.48% in 3 yrs
Forecast to 2030
6,134
Hypertension patients, 2030
+861 on today
65.0%
QRISK ≥20% on statins, 2030
-2.20pp over 3 yrs
4.7%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Age-five MMR dose difference below 95.0% target.
In Q1 2025/26, age-5 MMR2 is 87.6% against 91.8% for MMR1, below the 95.0% target by 7.4 pp, which may reflect recall gaps.
Phone contact ease varies widely across practices.
GPPS phone ease spans from 41.3% at Matrix Medical Practice to 61.9% at King George Road Surgery, which could reflect triage or demand.
Hypertension threshold treatment rose faster than comparators.
From 2023 to 2025, hypertension treatment to threshold rose +10.8% (Medway (LAD) +2.7%, ICB +1.4%, England +3.6%), reaching 69.3% across the registered cohort.
Population, age and ethnicity
Children comprise 22.9% of registered patients while older adults account for 16.5%
Across 33,476 registered patients, 22.9% are aged 0-17, above Medway (LAD) at 21.6%, NHS Kent and Medway ICB at 20.7% and England at 19.6%. Older adults aged 65+ represent 16.5%, below Medway (LAD) at 17.9%, the ICB at 19.9% and England at 17.9%. Census area data shows an 18.7% ethnic minority share, including 7.4% Black residents (Medway (LAD) 5.6%, ICB 3.1%, England 4.2%) and 6.6% Asian residents (Medway (LAD) 5.9%, ICB 4.7%, England 9.6%). List size is projected to grow 11.6% by 2030 under an unverified methodology. Ethnicity reflects area residents, not registered patients.
Age profile
65+: ICB 19.9%, England 17.9%
Ethnicity
Older people · falls rows are Medway (LAD) local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Medway LA) | 1,507 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 83.0% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 54.2% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Medway LA) | 740 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Medway LA) | 19.5 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation reaches 28.2% and concentrates heavily across two practices
Core20 patients comprise 28.2% of registered patients across the PCN, above Medway (LAD) (23.1%), NHS Kent and Medway ICB (17.1%), and England (21.0%). Deprivation varies by 36.4 pp between practices: The Churchill Clinic has 38.8% (estimated 3,770 patients) and Matrix Medical Practice has 32.4% (5,453 patients), whereas King George Road Surgery has 2.4% (164 patients). Practice-level estimates sum to 9,387 registered patients compared with 7,410 resident Core20 patients, reflecting different denominators. Proactive multidisciplinary support could prioritise practices with concentrated Core20 volume after reconciling lists.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
299
SMI register
0.91% recorded prevalence
207
Learning disability register
0.63% recorded prevalence
26
Care homes, 533 beds
In the PCN catchment
8.9%
Provide unpaid care
Medway (LAD), Census 2021
Recorded registers include 207 learning disability patients (0.6%, matching England 0.6%) and 299 severe mental illness patients (0.9% vs 1.0% England). Catchment areas contain 26 care homes with 533 beds, though resident registrations are unverified locally. At borough level, Medway records an 8.9% unpaid care rate and 11 rough sleepers.
Severe mental illness: physical health checks
Across 299 SMI patients, 82.9% had a BP check (England 83.4%) and 81.2% a BMI check (England 82.1%). Matrix Medical Practice records 65.4% for BP and 61.5% for BMI.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
5,273
Hypertension register
+1.77%
Register growth, 3 yrs
Medway (LAD) +3.74% · England +5.60%
+7.09pp
BP control, under 80
≤140/90 · +5.67pp aged 80+
+861
More patients by 2030
Forecast 6,134 (16.62%)
Hypertension case-finding and control
Hypertension prevalence is 16.1% (5,273 patients), above England (15.2%) and Medway (LAD) (15.4%), but register growth over three years was +1.8%, trailing England (+5.6%) and Medway (LAD) (+3.7%). Blood pressure control to 140/90 mmHg for patients under 80 improved +11.8% over three years to 67.2%, below England (67.8%) but above Medway (LAD) (65.3%), while practice rates vary from 60.7% at Matrix Medical Practice to 79.5% at King George Road Surgery. Lower control than England and wide practice variation mean Matrix Medical Practice offers the clearest opportunity for targeted blood pressure recall.
Lipids and statins
Lipid-lowering therapy for QRISK ≥ 20% is 69.2% (England 63.6%), but three-year coverage fell 3.1% (England +6.2%). Diabetic primary prevention statins also fell 2.8% to 77.6% (England +2.1%). Trailing three-year trends behind England may indicate recall gaps, which clinical audit would test.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 60,153 | £2.30 | £1.90 | £1.86 | £138,352 |
| Cardiovascular (all), 2025 | 69,950 | £2.70 | £3.57 | £3.33 | £188,865 |
In 2026, the PCN prescribed 60,153 lipid-regulating items at £2.30 per item (£138,352 spend), above England (£1.86), Medway (LAD) (£1.87), and NHS Kent and Medway ICB (£1.90). Across these items, the PCN spends £26,467 more than at England's unit cost. This unit-cost indicator reflects expenditure against national rates, though it does not establish efficiency, case mix, or formulary suitability.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−0.90%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+0.24%
Asthma prevalence, PCN 3-yr % change
The PCN records 1,905 asthma patients (6.2% prevalence; England 6.6%) and 756 COPD patients (2.3%; England 1.9%). Review coverage is 67.8% for asthma (England 65.7%) and 79.9% for COPD (England 76.4%). Over three years, reviews fell 0.9% for asthma (England +4.4%) and 4.5% for COPD (England +2.8%). An estimated 614 asthma patients lacked reviews, while prescribing for ages 5-19 reached 1,691 items per 1,000 (England 1,488). Trailing trends could reflect recall gaps, which local audit would test.
Cancer register and children's immunisation
Cancer prevalence is 3.9% (1,289 patients; England 3.8%). In Q1 2025/26, 6-in-1 immunisation coverage at 24 months was 89.2% (England 92.2%, ICB 93.4%), below the 95.0% target by 5.8 pp. Among children aged 5, MMR dose 1 coverage was 91.8% and dose 2 was 87.6%, reflecting a 4.2 pp same-cohort drop.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Kent and Medway ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,630
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Kent and Medway ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 82.1% | 85.4% | 23% | 1,509 |
| Prostate | 54.4% | 53.2% | 37% | 1,435 |
| Lung | 29.4% | 33.8% | 21% | 1,109 |
| Bowel | 48.2% | 47.0% | 29% | 1,013 |
| Skin cancer | 87.5% | 87.8% | 23% | 562 |
In 2022, NHS Kent and Medway ICB recorded 55.6% of cancers diagnosed at stage 1 or 2 (4,661 of 8,384 staged cancers; England 55.3%), sitting 19.4 pp below the 75.0% national ambition by 2028. Staged cases covered 63.6% of 13,189 registered ICB cancers, with 1,627 extra early-stage cases needed to reach 75.0%. This system metric reflects ICB staging, not PCN performance. In primary care, breast screening is 67.1% (England 69.9%, ICB 71.6%) despite +17.7% three-year change (England +8.4%), with The Churchill Clinic at 60.7%. Cervical screening is 71.6% (England 66.8%). Lower breast screening uptake across the network highlights an opportunity to review recall systems at lagging practices.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In provisional Jul 2026 data, Medway NHS Foundation Trust achieved 77.8% on the 28-day faster diagnosis standard (standard 75.0%; Dartford and Gravesham NHS Trust 78.1%, Maidstone and Tunbridge Wells NHS Trust 81.8%, ICB 76.8%, England 79.3%) and 99.6% on the 31-day standard (standard 96.0%; ICB 95.8%, England 92.5%). The 62-day referral to treatment standard reached 81.6% (standard 85.0%; Dartford and Gravesham NHS Trust 63.6%, Maidstone and Tunbridge Wells NHS Trust 87.4%, ICB 75.9%, England 71.2%). Across all diagnostic tests, 14.2% waited 6+ weeks (England 23.1%), although echocardiography was 36.6%. These provider metrics describe acute system performance.
| Pathways within standard (%) | Medway | Maidstone and Tunbridge Wells | Dartford and Gravesham | Kent and Medway ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 77.77 | 81.78 | 78.14 | 76.78 | 79.32 |
| 31-day treatment (96%) | 99.62 | 98.35 | 97.48 | 95.84 | 92.50 |
| 62-day referral to treatment (85%) | 81.64 | 87.43 | 63.59 | 75.93 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Medway | Maidstone and Tunbridge Wells | Dartford and Gravesham | England |
|---|---|---|---|---|
| MRI | 0.68 | 0.92 | 0.36 | 21.40 |
| CT | 0.00 | 0.51 | 2.08 | 9.92 |
| Echocardiography | 36.62 | 2.57 | 3.90 | 28.48 |
| Colonoscopy | 1.88 | 19.80 | 0.40 | 30.83 |
| Gastroscopy | 3.32 | 24.03 | 0.00 | 29.02 |
| All 15 DM01 tests | 14.20 | 6.42 | 8.37 | 23.14 |
| Community services activity | Medway residents | Kent and Medway ICB |
|---|---|---|
| Care contacts | 43,510 | 254,055 |
| Referrals | 8,580 | 68,085 |
| Patients with a contact | 11,540 | 72,060 |
Community services (residents of Medway), Jun 2026 (provisional). In provisional Jun 2026 data, Medway recorded 31,250 community care activities and 43,510 community care contacts, while NHS Kent and Medway Integrated Care Board recorded 297,595 activities. Contacts with adults aged 65+ accounted for 62% of Medway residents' contacts (26,985 of 43,510). These experimental figures reflect local authority and ICB service activity among submitting providers rather than registered PCN patients.
Practice variation and patient experience
Practice phone ease spans 20.6 pp while vaccination achievement remains below England benchmarks
In 2025/26, QOF overall achievement ranged from 78.2% at Matrix Medical Practice to 91.0% at The Churchill Clinic and 91.7% at King George Road Surgery (England 92.5%). Vaccination and immunisation achievement trailed England (55.2%) across all three practices, spanning 11.7 pp from 20.2% at The Churchill Clinic to 31.9% at Matrix Medical Practice.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Matrix Medical | 114 | 32.4 | 41.3% | 42.2% | 78.0% |
| King George Road | 108 | 2.4 | 61.9% | 62.6% | 75.8% |
| Churchill Clinic | 98 | 38.8 | 49.8% | 59.1% | 63.5% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
12 of 25 trends trail England, led by lipid therapy and respiratory reviews
Across 25 compared measures, 12 three-year trends trail England. QRISK ≥ 20% lipid therapy fell 3.1% (England +6.2%), COPD reviews fell 4.5% (England +2.8%), and asthma reviews fell 0.9% (England +4.4%). Psychosis alcohol recording rose +0.8 pp (England +5.4 pp). In contrast, heart failure reviews rose +30.8% (England +8.7%), reaching 81.8% current coverage, and learning disability prevalence rose +17.1% (England +5.4%). The PCN could review recall workflows and coding consistency across trailing clinical pathways before assuming patient access explains lower performance.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
QRISK statin treatment
COPD reviews
Asthma reviews
Diabetes statin (no CVD)
Alcohol record (psychosis)
Heart failure reviews
Breast screening (53-70)
BP control, under 80
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Medway (LAD) | Asset | PCN | Medway (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 26 (533 beds) | n/a | Schools (catchment) | 104 | n/a |
| Children's centres | 9 | 19 | Places of worship | 48 | 110 |
| Libraries | 4 | 9 | Food banks (VCS) | 4 | 6 |
| Homelessness support (VCS) | 6 | 9 | Day centres (VCS) | 17 | 29 |
| Children and young people (VCS) | 39 | 65 | Carers support groups (VCS) | 10 | 22 |
| Primary schools (LA maintained) | 9 | 17 | Primary academies | 23 | 56 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Age-five second MMR dose recall
In Q1 2025/26, age-5 MMR coverage dropped 4.2 pp from 91.8% (MMR1) to 87.6% (MMR2, 7.4 pp below the 95.0% target; cohort 97), including 6.7 pp at The Churchill Clinic. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 2
Structured asthma annual review recall
Asthma review coverage is 67.8% of the 1,905 register (England 65.7%), leaving an estimated 614 patients unreviewed as 3-year coverage fell 0.9% (England +4.4%). For discussion, the PCN could pair structured asthma recall with inhaler prescribing checks and after-school slots at high-Core20 practices. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
Practice telephony and triage review
In the Jan-Apr 2026 survey, phone contact ease spanned 20.6 pp: 41.3% at Matrix Medical Practice, 49.8% at The Churchill Clinic, and 61.9% at King George Road Surgery (England 56.9%). For discussion, the PCN could audit inbound call queues, peak demand and online triage routing at the lowest-scoring practices. Moderate effort to run.
Evidence base: patient-reported access and experience is the demand-side signal on primary-care capacity and access model; practices with sustained poor experience are the ones to prioritise for access-model support.
Policy anchor: 10 Year Health Plan, shift from hospital to community (Neighbourhood Health Service).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension control review (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Second dose MMR recall outreach (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Breast screening recall review (p7) | Breast screening coverage: aged 53 to 70 years old | — | PCN |
| Practice telephony and triage audit (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Age-five second MMR dose recall (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Option 2 · Structured asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 Population | Core20PLUS5 respiratory | PCN |
| Option 3 · Practice telephony and triage review (p12) | GPPS easy to contact the practice by phone · GPPS survey response rate | 10YHP, hospital to community | Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
